Acquisitions, Mergers & PartnershipsBioprinting

Bioprinting company CELLINK acquires Dispendix for €5M

The acquisition of the biodispensing company will enable CELLINK to attain faster bioprinting rates

Stay up to date with everything that is happening in the wonderful world of AM via our LinkedIn community.

Swedish 3D bioprinting company CELLINK has today announced it has acquired German biodispensing tech company Dispendix GmbH for €5 million. The deal will see CELLINK buy all of Dispendix’s shares and add the company’s technologies to its own bioprinting solutions.

Dispendix’s technology, its patented Immediate Drop on Demand Technology (IDOT), is designed to speed up drug testing processes. The IDOT process itself was developed over the course of 10 years at the Fraunhofer Institute, and Dispendix launched the platform’s first commercial product in 2017, the I-DOT One. This product has a range of dispensing applications, including Cell Dispensing, Matrigel Dispensing, Array Generation and more.

In acquiring the German company, CELLINK will add Dispendix’s technology to its own portfolio (which includes the Bio X printer and various bioinks) to increase the dispensing rate of bioinks. IDOT’s ability to dispense single cells will also enable CELLINK and its clients to build micro tissues faster and more reproducibly.

“Our innovative products for non-contact, high throughput dispensing and CELLINK ́s comprehensive bioprinting technologies will [extend] and provide additional applications to researchers in the life science industry,” said Harry Boeltz, CEO and Co-founder of Dispendix. “Customers will benefit from a united company that has a common passion for the commitment to outstanding service and support.”

CELLINK Dispendix
Dispendix’s IDOT technology

Dispendix’s products will reportedly fit seamlessly into CELLINK’s bioprinting portfolio and will be targeted primarily towards pharmaceutical companies, which will benefit from rapid bioink dispensing. Through the acquisition, CELLINK aims to increasingly hone in on the pharmaceutical market.

“With this strategic acquisition, we are looking forward to taking a new step in CELLINK’s development focusing on the pharmaceutical industry,” said Erik Gatenholm, CEO of CELLINK. “The Dispendix technology platform complements CELLINK’s product range well and increases the uses of our innovative bioink through higher reproducibility and the ability to print more relevant tissue structures. Together, both companies to be stronger and able to offer a more comprehensive solution for both academic and pharmaceutical customers worldwide.”

The €5 million acquisition will be paid out partly in cash (€2M) and partly through CELLINK shares. As per the deal, the shares will be covered by a three-year lock-up (100% of the shares will be under lock-up for one year, 70% for two years and 40% for three years).

CELLINK has stated that it believes the addition of Dispendix to its business will add about €1.16 million (SEK 12 million) to the new group’s net sales in the 2018/2019 financial year. Dispendix estimates to have a profit-neutral impact on the group during the same financial year, as the company is focusing on the development of new products.

Research 2022
Polymer AM Market Opportunities and Trends

741 unique polymer AM companies individually surveyed and studied. Core polymer AM market generated $4.6 billion...

Tess Boissonneault

Tess Boissonneault is a Montreal-based content writer and editor with five years of experience covering the additive manufacturing world. She has a particular interest in amplifying the voices of women working within the industry and is an avid follower of the ever-evolving AM sector. Tess holds a master's degree in Media Studies from the University of Amsterdam.

Related Articles

Back to top button

We use cookies to give you the best online experience and for ads personalisation. By agreeing you accept the use of cookies in accordance with our cookie policy.

Privacy Settings saved!
Privacy Settings

When you visit any web site, it may store or retrieve information on your browser, mostly in the form of cookies. Control your personal Cookie Services here.

These cookies are necessary for the website to function and cannot be switched off in our systems.

In order to use this website we use the following technically required cookies
  • wordpress_test_cookie
  • wordpress_logged_in_
  • wordpress_sec

Decline all Services
Accept all Services



Join industry leaders and receive the latest insights on what really matters in AM!

This information will never be shared with 3rd parties

I’ve read and accept the privacy policy.*